GCLGrace Chung-Yan LuiMBChB (Hons), FHKCP, FHKAMSlidesetAsia-Pacific HIV Clinical Forum 2019Challenges in Caring for HIV-TB Coinfected Patients - Grace Chung-Yan Lui, MBChB (Hons), FHKCP, FHKAMView Slideset
PCPedro CahnMD, PhDSlidesetAsia-Pacific HIV Clinical Forum 2019Reduced Drug Regimens - Pedro Cahn, MD, PhDView Slideset
NRNatella RakhmaninaMD, PhD, FAAP, FCP, AAHIVSSlidesetAsia-Pacific HIV Clinical Forum 2019INSTI Use in Women of Child-Bearing Age - NTD Toxicity - Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVSView Slideset
SlidesetAsia-Pacific HIV Clinical Forum 2019Dolutegravir Plus Tenofovir Disoproxil Fumarate/ Emtricitabine as HIV Post-Exposure Prophylaxis: Efficacy and Safety Results from Real World Study - Chongxi LiView Slideset
DCDonn ColbyMD, MPHSlidesetAsia-Pacific HIV Clinical Forum 2019Starting PrEP During Acute HIV Infection: What is the Risk for Antiretroviral Drug Resistance? - Donn ColbyView Slideset
DCDonn ColbyMD, MPHSlidesetAsia-Pacific HIV Clinical Forum 2019Transmitted drug resistance to integrase inhibitors is uncommon in both acute and chronic HIV infection in Bangkok - Donn ColbyView Slideset
KRKiat RuxrungthamMDSlidesetAsia-Pacific HIV Clinical Forum 2019Clinical experience INSTI in Thailand - Kiat Ruxrungtham, MDView Slideset
SOShinichi OkaMD, PhDSlidesetAsia-Pacific HIV Clinical Forum 2019Clinical experience INSTI in Japan S- Shinichi Oka, MD, PhDView Slideset
SlidesetAsia-Pacific HIV Clinical Forum 2019Trends of Genotypic Sensitivity Scores of HIV-1 in Taiwan: Potential Application in the Selection of Single-Tablet Antiretroviral Regimens - Kuan-Yeh LeeView Slideset
SlidesetAsia-Pacific HIV Clinical Forum 2019The Impact of Antiretroviral Drug Resistance in Taiwanese HIV-1-Infected MSM Population Between 2015 and 2018 - Yen-Ju ChenView Slideset
CBCharles BoucherMD, PhDSlidesetAsia-Pacific HIV Clinical Forum 2019Selected INSTI Highlights - CROI 2019 - Charles Boucher, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019Oral Prescription Opioid Use should be Considered a Risk Factor for HCV Infection: Another Step Toward HCV Elimination- B. HackView Slideset
